Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(3):159-160; doi:10.1093/jnci/djj060
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rice, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rice, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

New Data on Clinical Trials Directive in Europe Show Few Favorable Outcomes

Mary Rice

The first 10% of the full text of this article appears below.

Early predictions that the European Union Clinical Trials Directive would have a damaging effect on academic research seem to be coming true, Patrick Therasse, M.D., from the European Organization for Research and Treatment of Cancer in Brussels, Belgium, told the European Cancer Conference in Paris last fall.


Figure Removed (Available Only in the Full Text)
View larger version (119K):
[in this window]
[in a new window]
  		Patrick Therasse

 
The directive, a pan-European law that must be implemented in national legislation in all 25 European Union member states, was intended to simplify and harmonize clinical trials throughout Europe. Among the directive's requirements are the obligation that . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?